LXRX 10-Q: SEC filing
Lexicon Pharmaceuticals
Filed with the SEC on · accession 0001062822-26-000128
LXRX filed a 10-Q (quarterly report) with the SEC on Nov 5, 2026. Lexicon Pharmaceuticals filed its quarterly 10-Q report with standard CEO certification under Sarbanes-Oxley.
Summary of the filing
Lexicon Pharmaceuticals filed its quarterly 10-Q report with standard CEO certification under Sarbanes-Oxley. The certification confirms the accuracy of financial statements and the effectiveness of disclosure controls and internal controls over financial reporting.
Key details
✦ Ask GOAX AI about this filing — what it means for LXRX, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for LXRX?
Click hereFrequently asked questions
What did LXRX file with the SEC on Nov 5, 2026?
LXRX filed a 10-Q (SEC filing). Lexicon Pharmaceuticals filed its quarterly 10-Q report with standard CEO certification under Sarbanes-Oxley. The certification confirms the accuracy of financial statements and the effectiveness of disclosure controls and internal controls over financial reporting.
How do I read a 10-Q?
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
Other LXRX SEC filings
Get alerts when LXRX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days